Related Experiment Videos
Heat shock protein-peptide complexes for use in vaccines
M Heike1, B Noll, K H Meyer zum Büschenfelde
1I. Medizinische Klinik und Poliklinik der Johannes Gutenberg Universität Mainz, Federal Republic of Germany.
Journal of Leukocyte Biology
|August 1, 1996
Summary
Heat shock proteins like gp96 can present peptides to the immune system, priming CD8+ T cells. Vaccination with these heat shock protein-peptide complexes offers a way to target antigens across MHC barriers.
Area of Science:
- Immunology
- Molecular Biology
- Cellular Biology
Background:
- Heat shock proteins (HSPs) such as gp96, HSP70, and HSP90 bind various cellular peptides due to their chaperone activity.
- Experimental evidence suggests that HSP-peptide complexes can elicit immune responses against the chaperoned peptides.
Purpose of the Study:
- To investigate the mechanism by which HSP-peptide complexes induce immune responses.
- To explore the potential of HSP-peptide complex vaccination for therapeutic applications, particularly against shared tumor and viral antigens.
Main Methods:
- Vaccination studies using heat shock protein-peptide complexes.
- Analysis of antigen presentation pathways, including internalization by macrophages and processing for MHC class I presentation.
- Assessment of T cell priming, specifically CD8+ T cell responses.
Main Results:
- Vaccination with gp96-peptide complexes leads to the internalization of complexes by macrophages.
- Chaperoned peptides are processed and presented on MHC class I molecules, primarily priming CD8+ T cells.
- HSP-peptide complexes can present peptides independent of the host cell's MHC haplotype, enabling cross-MHC immunization.
Conclusions:
- HSP-peptide complexes, particularly gp96, represent a general mechanism for priming MHC class I-restricted T cells by antigen-presenting cells.
- This mechanism allows for cross-MHC immunization strategies, offering potential for targeting shared antigens like those found in tumors and viral infections.